Research location
Huntersville
North Carolina, United States
Advertisement
Research activity in Huntersville
North Carolina, United StatesCureCurrent currently publishes aggregate city-level research activity for this location: 271 trials and 316 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Huntersville
271 linked trials · page 1 of 6A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid TumorsNCT07749586 · 2026-07-29 · 1 site observation
RECRUITING
Anti-Ly6E Exatecan ADC M7437 in Advanced Solid TumorsNCT07360314 · 2026-02-13 · 1 site observation
RECRUITING
A Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Rilvegostomig in Adult Participants With Advanced Solid Tumors Previously Treated With Standard of Care TherapyNCT07161414 · 2025-11-25 · 1 site observation
RECRUITING
A Study to Assess the Adverse Events, Change in Disease Activity, and How Oral ABBV-711 Tablets Move Through the Body as a Monotherapy and in Combination With Intravenously Infused Budigalimab (ABBV-181), in Adults With Advanced Squamous TumorsNCT07241039 · 2025-11-20 · 1 site observation
RECRUITING
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway AlterationsNCT07109726 · 2025-09-23 · 1 site observation
RECRUITING
ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus TrastuzumabNCT06876714 · 2025-09-17 · 2 site observations
RECRUITING
Study of CP-383 in Patients With Advanced or Metastatic Solid TumorsNCT07030257 · 2025-08-27 · 1 site observation
RECRUITING
E-Mindfulness Approaches for Living After Breast CancerNCT06748222 · 2025-06-27 · 1 site observation
RECRUITING
Phase 1/2 Study of ETX-636 in Participants With Advanced Solid TumorsNCT06993844 · 2025-06-10 · 1 site observation
RECRUITING
A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory CarcinomasNCT06999187 · 2025-06-03 · 1 site observation
RECRUITING
A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe AsthmaNCT06977581 · 2025-05-20 · 1 site observation
RECRUITING
Dose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adults With Uncontrolled Asthma on Medium-to-High Dose Inhaled CorticosteroidsNCT06932263 · 2025-03-26 · 1 site observation
RECRUITING
A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)NCT06857942 · 2025-03-19 · 1 site observation
RECRUITING
A Study of DM002 in Patients With Advanced Solid TumorsNCT06751329 · 2025-02-17 · 1 site observation
RECRUITING
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology ClinicsNCT06418204 · 2025-01-30 · 1 site observation
RECRUITING
Safety and Preliminary Effectiveness of BNT317, an Investigational Therapy for Advanced Solid TumorsNCT06750185 · 2025-01-13 · 1 site observation
RECRUITING
The CDK4/6 Inhibitor Dosing Knowledge (CDK) StudyNCT06377852 · 2024-10-29 · 1 site observation
RECRUITING
Study of XB010 in Subjects With Solid TumorsNCT06545331 · 2024-08-06 · 1 site observation
RECRUITING
A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary DiseaseNCT06283966 · 2024-02-21 · 1 site observation
RECRUITING
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25NCT05879926 · 2023-10-18 · 3 site observations
RECRUITING
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid TumorsNCT06040541 · 2023-09-07 · 1 site observation
RECRUITING
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung CancerNCT05624996 · 2023-07-12 · 2 site observations
RECRUITING
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus PembrolizumabNCT05812807 · 2023-06-14 · 3 site observations
RECRUITING
Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)NCT05431270 · 2022-08-11 · 1 site observation
RECRUITING
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic CancerNCT05267626 · 2022-04-04 · 1 site observation
RECRUITING
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab AdizutecanNCT05005403 · 2021-11-01 · 1 site observation
RECRUITING
GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid TumorsNCT04977453 · 2021-08-02 · 1 site observation
RECRUITING
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)NCT04852887 · 2021-06-23 · 1 site observation
RECRUITING
Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic TumorsNCT04777994 · 2021-03-09 · 1 site observation
RECRUITING
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung CancerNCT04181060 · 2020-12-28 · 1 site observation
RECRUITING
A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4NCT07218003 · 2025-11-17 · 1 site observation
ENROLLING_BY_INVITATION
Clinical Study of Ensifentrine-Glycopyrrolate (MK-5884A/RPL554) Fixed-dose Combination Dose Ranging in Participants With COPD (MK-5884A-029/RPL554-CO-212)NCT07016412 · 2025-07-31 · 1 site observation
COMPLETED
A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D MutationNCT07023731 · 2025-05-29 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study to Assess the Potential for Airway Sensitivity Reactions With Propellants HFA-152a (Test) and HFA-134a (Reference) Administered Via Pressurized Inhalers in Adults With Mild AsthmaNCT06702462 · 2025-03-11 · 1 site observation
COMPLETED
Testing Low Dose Tamoxifen for Invasive Breast Cancer, LoTam TrialNCT06671912 · 2025-02-19 · 1 site observation
SUSPENDED
Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or OverweightNCT06588283 · 2024-09-30 · 1 site observation
COMPLETED
A Study to Evaluate Solrikitug in Participants With COPD (ZION)NCT06496620 · 2024-08-14 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study to Investigate APL-5125 in Adults With Advanced Solid TumorsNCT06399757 · 2024-06-18 · 1 site observation
COMPLETED
Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid TumorsNCT06334432 · 2024-03-14 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study to Assess Adverse Events, and How Intravenously (IV) Infused ABBV-969 Moves Through the Bodies of Adult Participants With Metastatic Castration-Resistant Prostate CancerNCT06318273 · 2024-03-08 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study to Investigate the Efficacy and Safety of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALIANT)NCT06196879 · 2024-02-27 · 1 site observation
COMPLETED
A Study to Assess the Safety, Pharmacokinetics, and Efficacy of Intravenous (IV) ABBV-303, as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181), in Adults With Advanced Solid TumorsNCT06158958 · 2024-02-06 · 1 site observation
TERMINATED
A Study to Investigate Long-term Safety and Tolerability of Itepekimab in Participants With COPDNCT06208306 · 2024-01-11 · 1 site observation
COMPLETED
Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of ExacerbationsNCT06040086 · 2023-09-22 · 1 site observation
COMPLETED
A Study to Evaluate Efficacy and Safety of GSK3858279 in Diabetic Peripheral Neuropathic PainNCT05838755 · 2023-09-20 · 1 site observation
TERMINATED
A First-in-Human Study of SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid TumorsNCT05989724 · 2023-09-19 · 1 site observation
UNKNOWN
A Study to Evaluate the Efficacy, Safety, Participant Choice and Preference of an Oral Once-daily Regimen or a Long-acting Injectable Regimen Every Two Months for Treatment of Human Immunodeficiency Virus (HIV-1) in Adults Who Have Not Previously Taken Antiretroviral TherapyNCT05917509 · 2023-07-06 · 1 site observation
COMPLETED
A Dose Escalation/Expansion Study of MDK-703 in Patients With Advanced or Metastatic Solid TumorsNCT05716295 · 2023-02-08 · 1 site observation
TERMINATED
A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Eosinophilic AsthmaNCT05748600 · 2023-01-30 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of ALRN-6924 for Protection of Chemotherapy-Induced Side Effects in Patients With TP53-Mutant Breast CancerNCT05622058 · 2023-01-09 · 1 site observation
TERMINATED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.